{"id":67787,"date":"2026-06-09T22:54:04","date_gmt":"2026-06-09T14:54:04","guid":{"rendered":"https:\/\/flcube.com\/?p=67787"},"modified":"2026-06-09T22:54:05","modified_gmt":"2026-06-09T14:54:05","slug":"adcentrx-therapeutics-receives-nmpa-ind-clearance-for-steap1-targeting-adc-adrx-0405-in-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67787","title":{"rendered":"Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Adcentrx Therapeutics<\/strong> announced today that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has cleared the company&#8217;s <strong>Investigational New Drug (IND)<\/strong> application for <strong>ADRX-0405<\/strong>, enabling inclusion of China-based clinical centers in its ongoing Phase 1a\/1b trial (NCT06710379) evaluating the potential first-in-class antibody-drug conjugate (ADC) in patients with late-stage solid tumors.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Candidate<\/strong><\/td><td>ADRX-0405<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Adcentrx Therapeutics<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>IND clearance<\/td><\/tr><tr><td><strong>Target Indications<\/strong><\/td><td>Metastatic castration-resistant prostate cancer, gastric cancer, and non-small cell lung cancer<\/td><\/tr><tr><td><strong>Trial Identifier<\/strong><\/td><td>NCT06710379 (Phase 1a\/1b)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<h3 id=\"h-steap1-targeting-innovation\" class=\"wp-block-heading\">STEAP1-Targeting Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: Six-transmembrane epithelial antigen of the prostate 1 (STEAP1)<\/li>\n\n\n\n<li><strong>Expression Profile<\/strong>: Overexpressed in prostate cancer and certain other solid tumors with limited expression in healthy tissue<\/li>\n\n\n\n<li><strong>Therapeutic Class<\/strong>: Potential first-in-class, next-generation antibody-drug conjugate (ADC)<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Novel target with favorable tumor-to-normal tissue selectivity ratio<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-plan\" class=\"wp-block-heading\">Clinical Development Plan<\/h2>\n\n\n\n<h3 id=\"h-phase-1a-1b-trial-design\" class=\"wp-block-heading\">Phase 1a\/1b Trial Design<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Type<\/strong><\/td><td>Open-label, multicenter, dose escalation and expansion<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Select advanced solid tumors including mCRPC, gastric cancer, and NSCLC<\/td><\/tr><tr><td><strong>Primary Objectives<\/strong><\/td><td>Safety\/tolerability assessment and optimal dose determination<\/td><\/tr><tr><td><strong>Geographic Expansion<\/strong><\/td><td>Addition of China-based clinical centers following NMPA clearance<\/td><\/tr><tr><td><strong>Timeline<\/strong><\/td><td>Phase 1a completion anticipated Q4 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Development Strategy<\/strong>: Integration of Chinese clinical sites accelerates patient enrollment and supports global regulatory filings<\/li>\n\n\n\n<li><strong>Prostate Cancer Focus<\/strong>: Addresses significant unmet need in metastatic castration-resistant prostate cancer (mCRPC)<\/li>\n\n\n\n<li><strong>Target Validation<\/strong>: STEAP1 represents emerging target with strong biological rationale in multiple solid tumor types<\/li>\n\n\n\n<li><strong>ADC Platform<\/strong>: Demonstrates Adcentrx&#8217;s capability to develop novel ADCs against challenging targets<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context\" class=\"wp-block-heading\">Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prostate Cancer Burden<\/strong>: China accounts for approximately 14% of global prostate cancer cases with rising incidence<\/li>\n\n\n\n<li><strong>ADC Pipeline Competition<\/strong>: Limited STEAP1-targeting agents in clinical development globally<\/li>\n\n\n\n<li><strong>Chinese Clinical Trials<\/strong>: Increasing importance of Chinese data for global regulatory submissions<\/li>\n\n\n\n<li><strong>Solid Tumor ADC Market<\/strong>: Rapidly expanding therapeutic area with multiple recent approvals and high commercial value<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-looking-statements\" class=\"wp-block-heading\">Forward-Looking Statements<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This brief contains forward-looking statements regarding clinical development, regulatory pathways, and strategic objectives. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and execution challenges in international clinical development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Adcentrx Therapeutics announced today that China&#8217;s National Medical Products Administration (NMPA) has cleared the company&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,4782,62],"class_list":["post-67787","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-adcentrx-therapeutics","tag-clinical-trial-approval-initiation"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Adcentrx Therapeutics announced today that China&#039;s National Medical Products Administration (NMPA) has cleared the company&#039;s Investigational New Drug (IND) application for ADRX-0405, enabling inclusion of China-based clinical centers in its ongoing Phase 1a\/1b trial (NCT06710379) evaluating the potential first-in-class antibody-drug conjugate (ADC) in patients with late-stage solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67787\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Adcentrx Therapeutics announced today that China&#039;s National Medical Products Administration (NMPA) has cleared the company&#039;s Investigational New Drug (IND) application for ADRX-0405, enabling inclusion of China-based clinical centers in its ongoing Phase 1a\/1b trial (NCT06710379) evaluating the potential first-in-class antibody-drug conjugate (ADC) in patients with late-stage solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67787\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-09T14:54:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-09T14:54:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67787#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67787\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors\",\"datePublished\":\"2026-06-09T14:54:04+00:00\",\"dateModified\":\"2026-06-09T14:54:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67787\"},\"wordCount\":367,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Adcentrx Therapeutics\",\"Clinical trial approval \\\/ initiation\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67787#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67787\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67787\",\"name\":\"Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-09T14:54:04+00:00\",\"dateModified\":\"2026-06-09T14:54:05+00:00\",\"description\":\"Adcentrx Therapeutics announced today that China's National Medical Products Administration (NMPA) has cleared the company's Investigational New Drug (IND) application for ADRX-0405, enabling inclusion of China-based clinical centers in its ongoing Phase 1a\\\/1b trial (NCT06710379) evaluating the potential first-in-class antibody-drug conjugate (ADC) in patients with late-stage solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67787#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67787\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67787#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Adcentrx Therapeutics announced today that China's National Medical Products Administration (NMPA) has cleared the company's Investigational New Drug (IND) application for ADRX-0405, enabling inclusion of China-based clinical centers in its ongoing Phase 1a\/1b trial (NCT06710379) evaluating the potential first-in-class antibody-drug conjugate (ADC) in patients with late-stage solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67787","og_locale":"en_US","og_type":"article","og_title":"Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors","og_description":"Adcentrx Therapeutics announced today that China's National Medical Products Administration (NMPA) has cleared the company's Investigational New Drug (IND) application for ADRX-0405, enabling inclusion of China-based clinical centers in its ongoing Phase 1a\/1b trial (NCT06710379) evaluating the potential first-in-class antibody-drug conjugate (ADC) in patients with late-stage solid tumors.","og_url":"https:\/\/flcube.com\/?p=67787","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-09T14:54:04+00:00","article_modified_time":"2026-06-09T14:54:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67787#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67787"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors","datePublished":"2026-06-09T14:54:04+00:00","dateModified":"2026-06-09T14:54:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67787"},"wordCount":367,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Adcentrx Therapeutics","Clinical trial approval \/ initiation"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67787#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67787","url":"https:\/\/flcube.com\/?p=67787","name":"Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-09T14:54:04+00:00","dateModified":"2026-06-09T14:54:05+00:00","description":"Adcentrx Therapeutics announced today that China's National Medical Products Administration (NMPA) has cleared the company's Investigational New Drug (IND) application for ADRX-0405, enabling inclusion of China-based clinical centers in its ongoing Phase 1a\/1b trial (NCT06710379) evaluating the potential first-in-class antibody-drug conjugate (ADC) in patients with late-stage solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67787#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67787"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67787#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67787"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67787\/revisions"}],"predecessor-version":[{"id":67788,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67787\/revisions\/67788"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}